| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Disposable IV sets & services | | | | | | | | 5.2 |
| IV infusion pump systems | | | | | | | | 26.3 |
| Patient monitoring systems | | | | | | | | 0.0 |
| Total revenues | 53.3 | 41.8 | 31.7 | 38.5 | 30.4 | 23.1 | 32.5 | 31.6 |
| Revenue growth [+] | 27.5% | 31.8% | -17.7% | 26.5% | 31.9% | -29.0% | 2.9% | 101.8% |
| Disposable IV sets & services | | | | | | | | 84.5% |
| IV infusion pump systems | | | | | | | | 105.5% |
| Cost of goods sold | 12.0 | 9.8 | 8.1 | 8.8 | 7.2 | 5.6 | 6.2 | 5.8 |
| Gross profit | 41.3 | 32.0 | 23.6 | 29.7 | 23.2 | 17.5 | 26.3 | 25.8 |
| Gross margin | 77.4% | 76.6% | 74.3% | 77.1% | 76.3% | 75.9% | 81.1% | 81.5% |
| Selling, general and administrative [+] | 23.4 | 20.3 | 22.4 | 19.6 | 15.7 | 14.5 | 14.1 | 12.5 |
| Sales and marketing | 12.7 | 10.6 | 10.2 | 9.2 | 7.0 | 5.5 | 5.3 | 4.7 |
| General and administrative | 10.7 | 9.8 | 12.3 | 10.5 | 8.7 | 9.0 | 8.8 | 7.8 |
| Research and development | 2.3 | 1.9 | 1.9 | 1.4 | 1.5 | 1.7 | 1.3 | 1.8 |
| EBITDA [+] | 16.3 | 11.2 | 0.6 | 9.9 | 7.1 | 2.6 | 11.9 | 12.3 |
| EBITDA growth | 45.2% | 1826.2% | -94.1% | 39.1% | 174.1% | -78.2% | -3.6% | 283.2% |
| EBITDA margin | 30.6% | 26.8% | 1.8% | 25.7% | 23.4% | 11.2% | 36.5% | 39.0% |
| Depreciation | 0.6 | 1.3 | 1.2 | 1.2 | 1.0 | 1.2 | 0.9 | 0.8 |
| EBITA | 15.7 | 9.9 | -0.7 | 8.7 | 6.1 | 1.4 | 10.9 | 11.5 |
| EBITA margin | 29.5% | 23.7% | -2.1% | 22.7% | 20.0% | 5.9% | 33.7% | 36.6% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| EBIT [+] | 15.6 | 9.8 | -0.8 | 8.6 | 6.0 | 1.3 | 10.9 | 11.5 |
| EBIT growth | 59.2% | -1398.5% | -108.7% | 44.0% | 367.2% | -88.2% | -5.2% | 275.5% |
| EBIT margin | 29.3% | 23.5% | -2.4% | 22.5% | 19.7% | 5.6% | 33.6% | 36.4% |
| Interest income | 0.6 | 0.0 | 0.1 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 |
| Interest income | 0.6 | 0.0 | 0.1 | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 |
| Other income (expense), net | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 |
| Pre-tax income | 16.2 | 9.8 | -0.6 | 9.0 | 6.2 | 1.4 | 11.0 | 11.6 |
| Income taxes | 3.4 | 0.5 | -2.0 | -0.6 | -0.1 | 0.9 | 3.7 | 4.1 |
| Tax rate | 20.7% | 5.2% | 321.9% | | | 64.2% | 34.1% | 35.3% |
| Net income | 12.8 | 9.3 | 1.4 | 9.6 | 6.3 | 0.5 | 7.2 | 7.5 |
| Net margin | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% | 23.8% |
| |
| Basic EPS [+] | $1.02 | $0.76 | $0.11 | $0.85 | $0.59 | $0.05 | $0.67 | $0.68 |
| Growth | 35.2% | 568.9% | -86.8% | 45.7% | 1147.2% | -93.0% | -2.6% | 191.8% |
| Diluted EPS [+] | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 | $0.60 |
| Growth | 37.1% | 573.0% | -86.0% | 50.7% | 1120.7% | -92.9% | 0.3% | 198.9% |
| |
| Dividends per share | $1.00 | | | | | | | |
| |
| Shares outstanding (basic) [+] | 12.6 | 12.3 | 12.1 | 11.3 | 10.8 | 10.6 | 10.8 | 11.0 |
| Growth | 1.8% | 1.8% | 7.5% | 4.9% | 1.1% | -1.7% | -1.7% | 25.8% |
| Shares outstanding (diluted) [+] | 12.6 | 12.6 | 12.4 | 12.3 | 12.1 | 11.7 | 12.0 | 12.6 |
| Growth | 0.4% | 1.2% | 1.3% | 1.4% | 3.3% | -2.2% | -4.5% | 22.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |